EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Prevalence, Determinants and Outcomes of Intravenous-to-Oral Switch of Antibiotic Therapy in Hospitalized Adults With Bloodstream Infection: Secondary Analysis of a Multicenter Cohort

Lea A Nikolai, Beryl P Gladstone, Sarah V Walker, Jörg J Vehreschild, Kristina Schmauder, Simone Eisenbeis, Alexander Mischnik, Evelyn Kramme, Christine Geffers, Siegbert Rieg, Trinad Chakraborty, Maria J G T Vehreschild, Harald Seifert, Jan Rupp, Silke Peter, Winfried V Kern, Evelina Tacconelli, Daniel Hornuss, Siri Göpel, Elke Lemke, Norbert Thoma, Solvy Wolke, Can Imirzalioglu, Susanne Herold, Nicole Tewes, Moritz Fritzenwanker, Annika Classen, David Tobys, Paul Higgins, Nadja Käding, Benjamin Gebel, Lisa Höltig, Katharina Nagel, Larissa Künstle, Elisabeth Stoll, Ariane Dinkelacker, Gabriele Peyerl-Hoffmann, Georg Häcker, Heike Spitznagel, Sara Olawumi-Hutter

Open Forum Infectious Diseases · 2026-10-31 · 13 (11)

DOI: 10.1093/ofid/ofag666 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background Intravenous-to-oral switch (IVOS) is considered safe in selected patients with bloodstream infection (BSI) and provides operational advantages. Still, it is underused in many clinical settings. We evaluated IVOS patterns, associated factors, and clinical outcomes in patients with BSI. Methods Secondary data were analyzed from 2 prospective, multicenter cohort studies recruiting patients with BSI. IVOS was assessed on day 3 and 7 after positive blood culture. Eligibility for IVOS was based on infectious focus, clinical safe-switch criteria, and antimicrobial susceptibility. Risk factors for non-IVOS were studied using multivariable logistic regression. Results Among 3824 patients, 2770 were included in the secondary analysis, and 742 (19.4%) were eligible and evaluable for IVOS. By day 7, 240 patients (32.3%) underwent IVOS. Switch occurred on the day of discharge in 107 patients (44.6%), and 1 day before discharge in 46 (19.2%). The most commonly used oral agents were ciprofloxacin (75 patients [31.3%]), sultamicillin (56 [23.3%]), and cefuroxime axetil (27 [11.3%]). Barriers to IVOS on multivariable analysis included diabetes (odds ratio, 0.57 [95% confidence interval, .38–.88]; P = .01), chronic kidney disease (0.64 [.41–.99]; P = .048), Pitt bacteremia score ≥2 on day 3 (0.43 [.19–.97]; P = .04), and septic shock before day 7 (0.31 [.11–.87]; P = .03), while urogenital focus (2.22 [1.50–3.28]; P < .001) and 2 study centers were positively associated with IVOS. IVOS was associated with shorter length of stay (7 vs 12 days; P < .001) and a lower 28-day mortality rate. Conclusions In clinically stable patients with BSI, IVOS was infrequently implemented. Barriers to IVOS should be addressed as part of antimicrobial stewardship programs.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →